Rizatriptan is indicated for the acute treatment of migraine with or without aura in adults. 

Migraine

• The usual dose of Rizatriptan is 5mg or 10 mg. Doses should be separated by at least 2 hours; no more than 30 mg should be taken in any 24-hour period. 
• The safety of treating, on average, more than four headaches in a 30-day period has not been established. 
• Patients receiving propranolol: In patients receiving propranolol, the 5-mg dose of Rizatriptan should be used, up to a maximum of 3 doses in any 24-hour period. 

The most common side effects associated with rizatriptan are-

• Nausea
• Asthenia
• Sleepiness/ drowsiness/ somnolence
• Tingling or burning feeling (paresthesia)
• Headache
• Dry mouth

Nausea

Drowsiness

Paresthesia

Dry Mouth

Asthenia

• Rizatriptan should only be used where a clear diagnosis of migraine has been established. 
• Rizatriptan should not be given to patients with documented ischemic or vasospastic coronary artery disease because this class of compounds (5-HT1B/1D agonists) has the potential to cause coronary vasospasm.
• As with other 5-HT1B/1D agonists, sensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw have been reported after treatment with Rizatriptan.
• Within a few hours of receiving Rizatriptan, serious adverse cardiac events, including acute myocardial infarction, have been reported.
• Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients receiving other 5-HT1 agonists, with some resulting in death.
• Significant increases in systemic blood pressure, including hypertensive crisis, have been reported in patients with and without a history of hypertension treated with other 5-HT1 agonists on rare occasions.
• Triptans, including Rizatriptan, have been linked to the development of a potentially fatal serotonin syndrome.